N. Graham

发表

Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials

J. Silverberg, M. Ardeleanu, E. Simpson, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Targeting key proximal drivers of type 2 inflammation in disease

G. Yancopoulos, N. Stahl, G. Pirozzi, 2015, Nature Reviews Drug Discovery.

AB0252 Benefit of Sarilumab with csDMARDs on Patient Productivity in Work, Household Work and Family, Social, Leisure Activities in TNF-IR RA Patients

V. Strand, P. Mahajan, A. Kivitz, 2016 .

FRI0228 Sarilumab Dose Reduction To Manage Laboratory Abnormalities in An Open-Label Extension Study in RA Patients

M. Genovese, G. Burmester, J. Parrino, 2016 .

AB0251 Early Onset of Benefit by Patient-Reported Outcomes (PROs) with Sarilumab Treatment in RA

M. Kosinski, V. Strand, E. Keystone, 2016 .

P480 Correlations of itch with quality of life and signs of atopic dermatitis across dupilumab trials

M. Ardeleanu, L. Eckert, A. Gadkari, 2017 .

DUPILUMAB IMPROVES ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA, REGARDLESS OF EXACERBATION HISTORY

P. Kuna, M. Castro, J. Chao, 2018, Annals of Allergy, Asthma & Immunology.

Dupilumab Improves Asthma Control and Asthma-Related Quality of Life in Uncontrolled Persistent Asthma Patients Across All Baseline Exacerbation Rates

M. Castro, V. Joish, S. Jayawardena, 2017 .

Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility

M. Castro, S. Jayawardena, G. Pirozzi, 2017 .

D201 DUPILUMAB EFFICACY IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA AND SEROLOGIC EVIDENCE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS

J. Corren, M. Rice, L. Sher, 2019, Annals of Allergy, Asthma & Immunology.

Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

I. Hussain, M. Ardeleanu, S. Forman, 2017 .